Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuCNS-SC
- Development stage
- Discontinued
- Lead developer
- StemCells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral, Intraspinal, Subretinal
01
Overview
HuCNS-SC (Human Central Nervous System Stem Cells) is a cell therapy product consisting of purified, fetal-derived human neural stem cells. Developed by StemCells, Inc., these cells are isolated using fluorescence-activated cell sorting (FACS) to select for CD133+ and CD24-/lo populations. The therapeutic mechanism involves the cells' ability to engraft, migrate, and differentiate into functional neural cells—specifically oligodendrocytes for remyelination in Pelizaeus-Merzbacher disease (PMD), or to provide lysosomal enzymes in neuronal ceroid lipofuscinosis (Batten disease). In spinal cord injury (SCI) and age-related macular degeneration (AMD), the cells were intended to provide neurotrophic support and cellular replacement. Although early trials in PMD showed evidence of donor-derived myelination, the development program was terminated in 2016 after the Phase 2 Pathway study in chronic spinal cord injury failed to meet its primary endpoint, leading to the dissolution of StemCells, Inc.
- Brand names
- HuCNS-SC
- Other names
- Human Central Nervous System Stem Cells
Beyond the preview
Go deeper on HuCNS-SC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuCNS-SC.